lisocabtagene maraleucel + ibrutinib

Lisocabtagene maraleucel + ibrutinib is a combination therapy under investigation for the treatment of relapsed or refractory B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed chimeric antigen receptor (CAR) T cell therapy that genetically modifies a patient's own T cells to express a CAR targeting the CD19 antigen on B cells. This enables the immune system to recognize and destroy malignant B cells[1][4][5]. Ibrutinib is an oral small molecule Bruton’s tyrosine kinase inhibitor that blocks signaling pathways essential for cancer cell proliferation and survival[2][3]. The combination aims to enhance anti-tumor efficacy by leveraging both direct cytotoxicity from CAR-T cells and disruption of tumor-supportive signaling by ibrutinib. Clinical studies have shown promising response rates in heavily pretreated CLL/SLL patients, including those previously treated with BTK inhibitors like ibrutinib[6][8].

Brand names

Imbruvica

Other names

lisocabtagene maraleucel + ibrutinib